Mounjaro Tops Drug Sales, Lilly's Stock Soars

Eli Lillys Mounjaro skyrocketed to the top spot as the worlds best-selling drug, raking in a whopping $8.66 billion in Q1 sales, surpassing Mercks Keytruda by $7.9 billion. This surge more than doubled from last years $3.84 billion, driving Lillys total revenue up by 56% to $19.79 billion and net income soaring by 168%. Zepbound contributed $4.16 billion, and international sales boomed, particularly in China, which added Mounjaro to its reimbursement list, now reaching over 55 countries. With obesity affecting 16% of the global population, or over 1 billion people, demand for Mounjaro remains high, especially in the U.S., where 40.3% of adults qualify. Lillys new oral obesity pill Foundayo launched in April, already with 20,000 users and 8,000 doctors prescribing it, setting up revenue projections at $84.4 billion by 2027. The stock is looking promising for the long haul. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2a18b5f08f99547c